Last reviewed · How we verify

NCT06594003

Motor Sparing Techniques, Genicular Nerve Radiofrequency Ablation Has Emerged As a Viable Alternative to Conservative Therapy and Total Knee Arthroplasty

Not yet recruiting NA Last updated 19 September 2024
What this trial tests

NA trial testing Radiofrequency in Knee Osteoarthritis \(OA\) in 60 participants. Not yet recruiting.

Timeline
1 October 2024
Primary endpoint
1 October 2025
1 November 2026

Quick facts

Lead sponsorAssiut University
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designfactorial
Maskingnone
Primary purposetreatment
Enrollment60
Start date1 October 2024
Primary completion1 October 2025
Estimated completion1 November 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Adults 50 to 70, any sex, with Knee Osteoarthritis \(OA\). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There has recently been considerable interest in the role of radiofrequency ablation (RFA) of the genicular nerves for KOA. In the majority of previous studies, ablation was done via a radiofrequency technique using either fluoroscopy or ultrasound for only three genicular nerves, whereas the knee joint is also supplied by a few other nerves (11, 12). Interestingly, neurolytic agents can also be used to ablate the nerves, and are readily available, less costly, and need less logistic support

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Radiofrequency

Trials testing the same drug.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06594003.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing